Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell injection could ease thumb arthritis pain

NCT ID NCT06459063

Symptom relief Sponsor: Kaplan Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests an injection called Allocetra for osteoarthritis at the base of the thumb. The trial includes 46 adults aged 40 and older whose pain hasn't improved with standard treatments. Researchers are checking if the injection is safe and whether it can reduce pain and improve hand function compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Allocetra (a cell therapy injection)
What this could lead to
If it works, this could point toward a new injection to ease pain and improve hand function in people with thumb osteoarthritis.
What could go wrong
This is a very early, small study (46 people) focused mainly on safety. It's too soon to know if Allocetra actually helps, and it may not work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects eligible for this clinical study must fulfill all of the following: 1. Age 40 years or older. 2. Patients with OA of the first CMC joint of the target thumb (basal thumb joint) who have failed conventional therapies, with pain assessed when not taking analgesic medications. 3. Score of 6 or higher on the Functional Index for Hand Osteoarthritis (FIHOA). 4. X-ray confirming OA of the first CMC joint of the target thumb with a Grade of 2 or 3 according to Eaton classification. 5. Blood tests from up to three months before treatment within protocol-defined limits. Exclusion Criteria: Subjects not eligible for this study include those that have any of the following: 1. Any significant injury, fracture, surgery, active local infection, deformity, severe Carpal Tunnel Syndrome (CTS), DeQuervain's tenosynovitis, trigger finger, or a ganglion cyst of the target hand. 2. History of chondrocalcinosis in the target joint, concomitant rheumatic disease. 3. Previous intra-articular injection of steroid, hyaluronate, or other agent, into the target joint within 3 months prior to screening visit. 4. Other limb pain of unknown etiology, or clinically significant widespread pain syndrome, e.g., fibromyalgia. 5. Pain in the limb clinically assessed to arise from an origin which is not the affected thumb joint (wrist pain, shoulder pain, etc.). 6. Secondary OA such as gout, hemochromatosis, rheumatoid/psoriatic arthritis. 7. Bleeding disorders, cognitive disorder, neurologic disease or other major medical condition which may interfere with study participation, treatment, assessments, or results. 8. For women of childbearing potential, a positive pregnancy test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis thumb are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, hand

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis thumb

Contacts and locations

Locations

  • Kaplan Medical Center

    Rehovot, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.